secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001628280-22-004562
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Eric Warren as Chief Commercial Officer; salary $444K, bonus target 35%
--------------------------------------------------------------------------------

- Eric Warren appointed CCO effective March 1, 2022; he was previously VP US Sales and Marketing since Jan 2021.
- Annual base salary $444,000; eligible for annual bonus targeted at 35% of base salary.
- Severance: 1x base salary plus target bonus if terminated within 12 months after a Sale Event.
- Outside Sale Event: severance of 9 months' base salary plus COBRA contribution.
- Warren has experience at Sanofi, Merck, and Nabriva Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022004562/0001628280-22-004562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022004562/espr-20220301.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-004562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer